Powder: -20°C for 3 years | In solvent: -80°C for 1 year
APX2039 is an orally active fungal Gwt1 enzyme inhibitor and a prodrug of the novel Gwt2096 inhibitor APX1.APX2039 exhibits potent anti-Kryptococcal activity against C. neoformans and C. gattii.APX2039 exhibits potent antifungal activity and blocks the localization of GPI (glycosylphosphatidylinositol) anchored cell wall mannoproteins. APX2039 has potent antifungal activity and blocks the localization of GPI (glycosylphosphatidylinositol)-anchored cell wall mannoproteins.APX2039 can be used to study cryptococcal meningitis (CM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 197.00 | |
5 mg | In stock | $ 578.00 | |
10 mg | In stock | $ 828.00 | |
25 mg | In stock | $ 1,260.00 | |
50 mg | In stock | $ 1,690.00 | |
100 mg | In stock | $ 2,280.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 462.00 |
Description | APX2039 is an orally active fungal Gwt1 enzyme inhibitor and a prodrug of the novel Gwt2096 inhibitor APX1.APX2039 exhibits potent anti-Kryptococcal activity against C. neoformans and C. gattii.APX2039 exhibits potent antifungal activity and blocks the localization of GPI (glycosylphosphatidylinositol) anchored cell wall mannoproteins. APX2039 has potent antifungal activity and blocks the localization of GPI (glycosylphosphatidylinositol)-anchored cell wall mannoproteins.APX2039 can be used to study cryptococcal meningitis (CM). |
Synonyms | APX-2039, APX 2039 |
Molecular Weight | 362.36 |
Formula | C20H15FN4O2 |
CAS No. | 2342606-49-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 36.24 mg/mL (100 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
APX2039 2342606-49-7 Microbiology/Virology Antifungal APX-2039 APX 2039 inhibitor inhibit